欧美黄色网页,久久久久国产精品人妻aⅴ四季,免费精品视频在线

Cigna Files Antitrust Suit Over Pomalyst Monopoly BMS Cigna Cigna has filed a major antitrust lawsuit against Bristol Myers Squibb, accusing the company of anti-competitive tactics to delay generic competition for the blockbuster drug Pomalyst, costing payers billions.
FDA Probes Sarepta's Elevidys After Second Death FDA The FDA is investigating Sarepta’s gene therapy Elevidys after two patient deaths linked to acute liver failure, raising safety concerns and prompting regulatory review.
PureCycle Technologies Secures $300M for Global Recycling Expansion Capacity Capacity News PureCycle Technologies PureCycle Technologies secures $300M to build polypropylene (PP) recycling plants in the U.S., Belgium, and Thailand, aiming to recycle 500,000 tons annually by 2030 using patented solvent-based technology.
Bristol Myers Defends Cobenfy Amid Setbacks BMS Bristol Myers defends its antipsychotic drug Cobenfy despite a failed phase 3 trial and slowing prescriptions. The company remains optimistic, citing physician support and ongoing trials in Alzheimer’s, bipolar disorder, and autism.
ADC Therapeutics Restructures to Focus on Key Assets ADC Therapeutics layoffs layoff ADC Therapeutics is closing its UK research site and reducing its workforce by 30% to focus on its approved cancer drug Zynlonta and a prostate-specific membrane antigen ADC, discontinuing several early-stage programs.
BioNTech Acquires CureVac in $1.25B mRNA Deal BioNTech Biotech Vaccine BioNTech acquires CureVac in a $1.25 billion all-stock deal, expanding its mRNA cancer therapy pipeline and resolving ongoing litigation. The acquisition strengthens BioNTech’s oncology strategy and manufacturing capabilities.
HHS Cancels $590M Moderna Bird Flu Vaccine Deal Amid Trial Success Moderna HHS The U.S. HHS has canceled a $590M contract with Moderna for its bird flu vaccine, mRNA-1018, despite promising trial results. Moderna now seeks new funding to continue late-phase development.
Boundless Bio Cuts Staff as Lead Drug Faces Setbacks Boundless Bio Layoffs Boundless Bio restructures after setbacks in its lead oncology trials, laying off 33% of staff and shifting focus to a new drug combination strategy and advancing its kinesin degrader candidate BBI-940.
Biogen and City Therapeutics Forge $1B RNAi Partnership Biogen Biotech City Therapeutics Biogen has partnered with RNAi specialist City Therapeutics in a deal worth up to $1 billion to develop next-generation CNS drugs. The collaboration includes milestone payments, equity investment, and clinical development leadership.
Psychedelic Trial Shows 94% Remission Rate Gilgamesh Pharmaceutical Biotech Gilgamesh Pharmaceuticals’ GM-2505 achieved a 94% remission rate in a Phase 2a trial for major depressive disorder. The short-acting psychedelic showed significant, sustained improvements and favorable safety in 40 patients.

<Pre12 3 4 5 6 7 8...11 Next >

News Archives

All Categories

Agricultural News Industrial News Chemical Policy Cosmetic News Exhibition News Food News Science News Pharmaceutical News

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a

Industry News

HOT Topics